Tag: Competition

Displaying 1361 - 1380 of 2071 results.

Pages

Testifying today on behalf of the Federal Trade Commission before the U.S. House Judiciary Committee’s Subcommittee on Courts and Competition Policy, Bureau of Competition Director Richard A. Feinstein said that anticompetitive patent settlements in the U.S. pharmaceutical industry delay consumer...
On 2/2/2009, the Commission filed a complaint in federal district court challenging and agreement between Solvay Pharmaceuticals and two generic drug manufacturers in which Solvay paid for the delayed release of generic equivalents to its own testosterone-replacement drug, AndroGel,...
Federal Trade Commission Chairman Jon Leibowitz will participate in the eighth annual International Competition Network (ICN) conference in Zurich, Switzerland, from June 3-5, 2009. At the conference, senior government antitrust officials, private-sector antitrust experts from around the world,...
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune...
The Federal Trade Commission has authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein...
Following a public comment period, the Commission has approved a final consent order in the matter of BASF and Ciba Specialty Chemicals. The vote approving the final order was 4-0. (FTC File No. 081-0265; the staff contact is Wallace W. Easterling, Bureau of Competition, 202-326-2936; see press...
Federal Trade Commission staff have filed a comment stating that the amended version of proposed Louisiana House Bill 687, if enacted, would further restrict competition to provide dental care to underserved children in the state, without providing any countervailing benefits to consumers. The...
The Federal Trade Commission has formally dismissed the complaint in the Rambus matter. “While we remain disappointed by the decision of the Court of Appeals, we of course respect the Court’s opinion and will move forward,” said Richard A. Feinstein, Director of the Bureau of Competition. “The...
Federal Trade Commission Chairman Jon Leibowitz announced today that Ken Glazer, Senior Deputy Director of the Bureau of Competition, plans to leave the FTC this month. “Ken is a first-rate lawyer and antitrust thinker,” said Chairman Leibowitz. “We are grateful for his service to the public, his...
The Federal Trade Commission today issued a Revised Notice of Proposed Rulemaking (RNPRM) seeking public comment on a revised proposed rule that would prohibit market manipulation in the petroleum industry. The revised proposed rule would prohibit anyone from engaging in fraud or deceit in...
Following a public comment period, the Commission has approved a final consent order in the matter of National Association of Music Merchants, Inc. (NAMM). The vote approving the final order was 4-0. (FTC File No. 001-0203; the staff contact is William Lanning, Bureau of Competition, 202-326-3361...
The Federal Trade Commission’s Bureau of Competition has advised TriState Health Partners, Inc. (TriState), a physician-hospital organization based in Hagerstown, Maryland, that staff has no present intention to recommend that the Commission challenge the organization’s proposed clinical...
The Federal Trade Commission today announced the fifth and final hearing in a series exploring the evolving market for intellectual property. This hearing will be held May 4-5, 2009, on the campus of the University of California at Berkeley, in cooperation with the Berkeley Center for Law and...
The Federal Trade Commission has brought to a halt two peddlers of bogus cancer cures that were targeted during Operation False Cures, a law enforcement sweep announced last fall. The FTC charged the companies in the sweep with making unsupported claims that their concoctions treated, cured, or...
BASF has settled Federal Trade Commission charges that its proposed $5.1 billion acquisition of rival chemical manufacturer Ciba Holding Inc. would be anticompetitive and violate federal law by reducing competition in the worldwide markets for two high performance pigments. Under the terms of a...
BASF has settled Commission charges that its proposed $5.1 billion acquisition of rival chemical manufacturer Ciba Holding Inc. would be anticompetitive and violate federal law by reducing competition in the worldwide markets for two high performance pigments. Under the terms of a...
Federal Trade Commission Chairman Jon Leibowitz announced today that David P. Wales, Acting Director of the Bureau of Competition for the past nine months, will leave the FTC in May. “Dave has done a terrific job in leading the Bureau of Competition during an active period of antitrust enforcement...
Drug maker Bristol-Myers Squibb Company (BMS) will pay $2.1 million – the largest fine allowed by law – for failing to inform the Federal Trade Commission of agreements reached with Apotex, Inc., regarding potential generic competition to its blockbuster drug Plavix. BMS’s conduct violated a 2003...

Pages